Erectile Dysfunction Clinical Trial
Official title:
A Prospective Randomized Study Whether Low-energy Extracorporeal Shockwave Therapy (LI-ESWT) Can Increase Erectile Function in Patients After Radical Prostatectomy
Verified date | December 2019 |
Source | University of Southern Denmark |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this project is to verify the relationship between low intensity shock wave treatment (LI-SWT) and increased scores in self-assessment regarding to erectile function (ED) and sexual intercourse, in patients, who has undergone a radical prostatectomy (RP). The data will be obtained from patients using international accepted sexual questionnaires prior to the LI-SWT and 5, 12 and 24 weeks following treatment.
Status | Completed |
Enrollment | 38 |
Est. completion date | September 1, 2019 |
Est. primary completion date | August 1, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: - Erectile dysfunction for more than 6 months, - Time since prostatectomy must be at least 9 month - At least unilateral nerve-sparing RP. - Erection Hardness Score (EHS) less than 2 and an Index of Erectile Function (IIEF-5) score less than 17 - Age 20-80 years - have been in a relationship for more than 3 months. - Participant can give informed consent. Exclusion Criteria: - Men with ED due to other reason than RD (psychogenic, neurological pathology or organic ED etc.) - Rectal extirpation, radiation therapy to the pelvic area and recovery from any other cancer within the past 5 years are excluded. - Participants with heart disease prohibiting sexual activity or taking medication with antiandrogens, anticoagulant (apart from aspirin) or systemic use of glucocorticoids within 5 weeks. - ED treatment within the last 7 days (screening phase), oral medication, vacuum devices, injections. |
Country | Name | City | State |
---|---|---|---|
Denmark | Odense University Hospital (OUH) | Odense | Fyn |
Lead Sponsor | Collaborator |
---|---|
University of Southern Denmark |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Danish Prostate Symptoms Scoring scheme (DAN-PSS) | A 12 item questionsaires regarding lower urinary tracts symptoms. Used to access whether there is any additional effects of the treatment | 2 weeks prior first treatment | |
Other | Danish Prostate Symptoms Scoring scheme (DAN-PSS) | A 12 item questionsaires regarding lower urinary tracts symptoms. Used to access whether there is any additional effects of the treatment | 24 weeks after last treatment | |
Other | Pain sensation | All participants are asked by the investigator, shortly after treatment, if there were any pain sensations during the application of shockwaves. This will be notified on a scheme. | first treatment | |
Other | Pain sensation | All participants are asked by the investigator, shortly after treatment, if there were any pain sensations during the application of shockwaves. This will be notified on a scheme. | second treatment (1 week after first treatment) | |
Other | Pain sensation | All participants are asked by the investigator, shortly after treatment, if there were any pain sensations during the application of shockwaves. This will be notified on a scheme. | third treatment (2 week after first treatment) | |
Other | Pain sensation | All participants are asked by the investigator, shortly after treatment, if there were any pain sensations during the application of shockwaves. This will be notified on a scheme. | fourth treatment (3 week after first treatment) | |
Other | Pain sensation | All participants are asked by the investigator, shortly after treatment, if there were any pain sensations during the application of shockwaves. This will be notified on a scheme. | fifth treatment (4 week after first treatment) | |
Primary | Erection hardness score (EHS) Baseline | A five entity questionnaire to review the self-esteem of erection during sexual intercourse. The questionnaire will be mailed to the participants home adresses together with a return envelope. | 2 weeks prior first treatment | |
Primary | Erection hardness score first follow up | A five entity questionnaire to review the self-esteem of erection during sexual intercourse. The questionnaire will be mailed to the participants home adresses together with a return envelope. | 5 weeks after last treatment | |
Primary | Erection hardness score second follow up | A five entity questionnaire to review the self-esteem of erection during sexual intercourse. The questionnaire will be mailed to the participants home adresses together with a return envelope. | 12 weeks after last treatment | |
Primary | Erection hardness score third follow up | A five entity questionnaire to review the self-esteem of erection during sexual intercourse. The questionnaire will be mailed to the participants home adresses together with a return envelope. | 24 weeks after last treatment. | |
Secondary | The International index of erection function (IIEF-5) baseline | A fifteen item questionnaires to access data on erection function. Only question 1-5 will be used in for data interpretation. These item is also called til erection function domain (EF domain) | 2 weeks prior first treatment | |
Secondary | The International index of erection function (IIEF-5) first follow up | A fifteen item questionnaires to access data on erection function. Only question 1-5 will be used in for data interpretation. These item is also called til erection function domain (EF domain) | 5 weeks after last treatment | |
Secondary | The International index of erection function (IIEF-5) second follow up | A fifteen item questionnaires to access data on erection function. Only question 1-5 will be used in for data interpretation. These item is also called til erection function domain (EF domain) | 12 weeks after last treatment | |
Secondary | The International index of erection function (IIEF-5) third follow up | A fifteen item questionnaires to access data on erection function. Only question 1-5 will be used in for data interpretation. These item is also called til erection function domain (EF domain) | 24 weeks after last treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05366504 -
LiST Plus PRP Injection Therapy vs LiST Monotherapy for ED Treatment
|
Phase 2/Phase 3 | |
Recruiting |
NCT02573805 -
the Diagnostic Value of Rigiscan Test (Nocturnal Penile Tumescence and Rigidity, NPTR) in Chinese Males
|
N/A | |
Recruiting |
NCT02745808 -
Injectable Collagen Scaffoldâ„¢ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
Withdrawn |
NCT01967251 -
Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction
|
Phase 2 | |
Withdrawn |
NCT02579148 -
Collagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
Recruiting |
NCT02225548 -
Sagene 2014 - Parkinson's Disease and Erectile Dysfunction
|
Phase 4 | |
Completed |
NCT02587988 -
Trial to Evaluate the Efficacy and Safety of HCP1302
|
Phase 3 | |
Completed |
NCT01937871 -
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED)
|
Phase 3 | |
Completed |
NCT02945462 -
Bone Marrow Mesenchymal Stem Cells in Erectile Dysfunction (ED)
|
Phase 1 | |
Completed |
NCT01698684 -
Research Evaluating a PDE5 Inhibitor for Erectile Dysfunction
|
Phase 4 | |
Not yet recruiting |
NCT01321489 -
A Study to Evaluate a Possible Superiority Expressed by the Faster Onset of Action and the Efficacy and Safety of Sildenafil Citrate 20mg Sublingual Tablet in the Treatment of Erectile Dysfunction of Different Etiologies
|
Phase 3 | |
Completed |
NCT02226237 -
Effectiveness of Physiotherapy to Treat the Urinary Incontinence and Erectile Dysfunction Post Retropubic Prostatectomy
|
N/A | |
Completed |
NCT01230541 -
Effect of Udenafil on Spermatogenesis
|
Phase 1 | |
Terminated |
NCT01262833 -
Pudendal Assessment in Erectile Dysfunction
|
N/A | |
Completed |
NCT01037218 -
Treatment of Erectile Dysfunction II
|
Phase 3 | |
Completed |
NCT01037244 -
Treatment of Erectile Dysfunction I
|
Phase 3 | |
Recruiting |
NCT00313898 -
Effect of Sildenafil on Quality of Sexual Life in Mild to Normally Sexually Functioning Males
|
Phase 4 | |
Completed |
NCT00663728 -
Assessment of Duration of Erection With Vardenafil 10 mg
|
Phase 4 | |
Completed |
NCT00667979 -
Evaluating the Efficacy of Vardenafil in Subjects With Erectile Dysfunction (ED) Administered 12, 18 or 24 Hours Prior to Intercourse
|
Phase 4 | |
Completed |
NCT00421083 -
Efficacy and Safety of Tadalafil in Subjects With Erectile Dysfunction Caused by Spinal Cord Injury
|
Phase 3 |